Business Context and Reporting Period
Company: ENDRA Life Sciences Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2026
Reporting Period: Single event date (June 25, 2026)
The filing discloses a proposed merger of an ENDRA subsidiary with Noble Africa LLC, a wholly-owned subsidiary of ASP Isotopes, Inc. and an intermediate holding company for Renergen Limited.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate transaction announcement rather than periodic financial performance.
Material Changes
- Proposed Merger: Announcement of a proposed merger between an ENDRA subsidiary and Noble Africa LLC.
- Counterparty Structure: Noble Africa LLC is identified as a subsidiary of ASP Isotopes, Inc. and an intermediate holding company for Renergen Limited.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the transaction but does not include specific forward-looking guidance, financial projections, or management commentary within the text of the 8-K itself.
Risks and Contingencies: The filing notes that the information under Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. This limits the legal liability of the forward-looking statements contained in the press release.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific terms of the proposed merger.
- Verify the corporate structure and relationship between Noble Africa LLC, ASP Isotopes, Inc., and Renergen Limited.
- Confirm whether the merger requires shareholder approval or regulatory clearance.
- Check for subsequent filings regarding the status of the proposed transaction.